Home › Compound Library › Depo-Provera (DMPA Injection)

Depo-Provera (DMPA Injection)

Hormonal Contraceptiveprescriptionim · inferred

Depot medroxyprogesterone acetate 150 mg IM injection every 12 weeks. Very long half-life (~50 days). Returns to fertility can take 6-18 months after discontinuation. Suppresses ovulation for 14+ weeks per injection.

Projected serum levels — 150 mg, custom (shown daily)

Depo-Provera (DMPA Injection)
Depo-Provera (DMPA Injection) modeled serum levels, 150 mg custom (shown daily) over 121 days Population-based pharmacokinetic estimate. Steady state reached after approximately 99 days. 0 500 1k 1.5k 2k Day 0 Day 30 Day 61 Day 91 Day 121 Time on a regular schedule ≈ steady state · day 99
Depo-Provera (DMPA Injection) modeled serum levels with a loading dose of 450 mg, then 150 mg custom (shown daily) The first dose is larger so levels approach steady state faster. 0 500 1k 1.5k 2k Day 0 Day 30 Day 61 Day 91 Day 121 Time on a regular schedule

Maintenance schedule: 150 mg custom (shown daily) (im).

Loading schedule: 450 mg on day 1, then 150 mg custom (shown daily) — reaching therapeutic levels sooner.

Modeled steady state after ~99 days: peak ≈ 1.0k mg, trough ≈ 1.0k mg body load. Population-based estimate over 121 days for a 150 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Hormonal Contraceptive
Route modeled
IM
Model confidence
inferred
Half-life
50 days
Common dose
150 mg
Suggested maximum
150 mg/day
Reference dose range
75–150 mg (single dose)
Suggested cadence
custom (shown daily)
Validated against
150 mg im — Cmax 0.002 mg/L at 504 h

Documented interactions

  • contraindicated
    Carbamazepine (Tegretol) + Depo-Provera (DMPA Injection) CYP induction

    Carbamazepine (Tegretol) inducer of CYP3A4 predicted to change Depo-Provera (DMPA Injection) AUC by ~0.20x

  • contraindicated
    Clarithromycin (Biaxin) + Depo-Provera (DMPA Injection) CYP inhibition

    Clarithromycin (Biaxin) mechanism_based of CYP3A4 predicted to change Depo-Provera (DMPA Injection) AUC by ~10.00x

  • contraindicated
    Dasatinib (Sprycel) + Depo-Provera (DMPA Injection) CYP inhibition

    Dasatinib (Sprycel) time_dependent_inhibitor of CYP3A4 predicted to change Depo-Provera (DMPA Injection) AUC by ~5.00x

  • contraindicated
    Diltiazem + Depo-Provera (DMPA Injection) CYP inhibition

    Diltiazem mechanism_based of CYP3A4 predicted to change Depo-Provera (DMPA Injection) AUC by ~10.00x

  • contraindicated
    Efavirenz (Sustiva) + Depo-Provera (DMPA Injection) CYP induction

    Efavirenz (Sustiva) inducer of CYP3A4 predicted to change Depo-Provera (DMPA Injection) AUC by ~0.12x

  • contraindicated
    Grapefruit (whole fruit) + Depo-Provera (DMPA Injection) CYP inhibition

    Grapefruit (whole fruit) mechanism_based of CYP3A4 predicted to change Depo-Provera (DMPA Injection) AUC by ~10.00x

Serum checks 122 modeled interaction pairings for depo-provera (dmpa injection) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Pharmacokinetics of Depot Medroxyprogesterone Acetate Contraception Jain J et al. · Contraception, 2004 DOI

    Comprehensive PK study of DMPA 150mg IM showing peak levels at 3 weeks, slow elimination (t1/2 ~50 days), and serum levels remain contraceptive for 14+ weeks.

  2. Use of Depot Medroxyprogesterone Acetate Contraception and Incidence of Bone Fracture Meier C et al. · Journal of Clinical Endocrinology & Metabolism, 2010 DOI

    Large cohort study finding DMPA associated with modest bone density reduction that is largely reversible after discontinuation.

  3. Depot Medroxyprogesterone Acetate and Body Weight: A Systematic Review Lopez LM et al. · Contraception, 2009 DOI

    Systematic review of 22 studies finding average weight gain of <2 kg over 12 months on DMPA, with high individual variability.

3 published studies referenced in the app, each with a plain-language summary.